275 related articles for article (PubMed ID: 11105796)
1. Blood pressure reduction associated with preservation of renal function in hypertensive patients with IgA nephropathy: a 3-year follow-up.
Kanno Y; Okada H; Saruta T; Suzuki H
Clin Nephrol; 2000 Nov; 54(5):360-5. PubMed ID: 11105796
[TBL] [Abstract][Full Text] [Related]
2. Effects of angiotensin converting enzyme inhibitor on renal function in patients of membranoproliferative glomerulonephritis with mild to moderate renal insufficiency.
Giri S; Mahajan SK; Sen R; Sharma A
J Assoc Physicians India; 2002 Oct; 50():1245-9. PubMed ID: 12568207
[TBL] [Abstract][Full Text] [Related]
3. Interim evidence of the renoprotective effect of the angiotensin II receptor antagonist losartan versus the calcium channel blocker amlodipine in patients with chronic kidney disease and hypertension: a report of the Japanese Losartan Therapy Intended for Global Renal Protection in Hypertensive Patients (JLIGHT) Study.
Iino Y; Hayashi M; Kawamura T; Shiigai T; Tomino Y; Yamada K; Kitajima T; Ideura T; Koyama A; Sugisaki T; Suzuki H; Umemura S; Kawaguchi Y; Uchida S; Kuwahara M; Yamazaki T;
Clin Exp Nephrol; 2003 Sep; 7(3):221-30. PubMed ID: 14586719
[TBL] [Abstract][Full Text] [Related]
4. Dual renin-angiotensin system blockade plus oral methylprednisone for the treatment of proteinuria in IgA nephropathy.
Trimarchi H; Muryan A; Young P; Forrester M; Iotti A; Pereyra H; Lombi F; Seminario O; Alonso M; Iotti R
Medicina (B Aires); 2007; 67(5):445-50. PubMed ID: 18051227
[TBL] [Abstract][Full Text] [Related]
5. The effects of amlodipine and enalapril on renal function in adults with hypertension and nondiabetic nephropathies: a 3-year, randomized, multicenter, double-blind, placebo-controlled study.
Esnault VL; Brown EA; Apetrei E; Bagon J; Calvo C; DeChatel R; Holdaas H; Krcmery S; Kobalava Z;
Clin Ther; 2008 Mar; 30(3):482-98. PubMed ID: 18405787
[TBL] [Abstract][Full Text] [Related]
6. Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
Rahman M; Pressel S; Davis BR; Nwachuku C; Wright JT; Whelton PK; Barzilay J; Batuman V; Eckfeldt JH; Farber M; Henriquez M; Kopyt N; Louis GT; Saklayen M; Stanford C; Walworth C; Ward H; Wiegmann T
Arch Intern Med; 2005 Apr; 165(8):936-46. PubMed ID: 15851647
[TBL] [Abstract][Full Text] [Related]
7. Enalapril/amlodipine combination in cyclosporine-treated renal transplant recipients: a prospective randomized trial.
Halimi JM; Giraudeau B; Buchler M; Al-Najjar A; Etienne I; Laouad I; Bruyère F; Lebranchu Y
Clin Transplant; 2007; 21(2):277-84. PubMed ID: 17425758
[TBL] [Abstract][Full Text] [Related]
8. Initial angiotensin-converting enzyme inhibitor/calcium channel blocker combination therapy achieves superior blood pressure control compared with calcium channel blocker monotherapy in patients with stage 2 hypertension.
Jamerson KA; Nwose O; Jean-Louis L; Schofield L; Purkayastha D; Baron M
Am J Hypertens; 2004 Jun; 17(6):495-501. PubMed ID: 15177521
[TBL] [Abstract][Full Text] [Related]
9. Amlodipine/benazepril combination therapy for hypertensive patients nonresponsive to benazepril monotherapy.
Chrysant SG; Bakris GL
Am J Hypertens; 2004 Jul; 17(7):590-6. PubMed ID: 15233978
[TBL] [Abstract][Full Text] [Related]
10. Angiotensin-converting-enzyme inhibitors slow renal decline in IgA nephropathy, independent of tubulointerstitial fibrosis at presentation.
Kanno Y; Okada H; Yamaji Y; Nakazato Y; Suzuki H
QJM; 2005 Mar; 98(3):199-203. PubMed ID: 15728401
[TBL] [Abstract][Full Text] [Related]
11. Long-term follow-up of ACE-inhibitor versus beta-blocker treatment and their effects on blood pressure and kidney function in renal transplant recipients.
Suwelack B; Kobelt V; Erfmann M; Hausberg M; Gerhardt U; Rahn KH; Hohage H
Transpl Int; 2003 May; 16(5):313-20. PubMed ID: 12759722
[TBL] [Abstract][Full Text] [Related]
12. Decline of renal function is associated with proteinuria and systolic blood pressure in the morning in diabetic nephropathy.
Suzuki H; Kanno Y; Nakamoto H; Okada H; Sugahara S
Clin Exp Hypertens; 2005; 27(2-3):129-38. PubMed ID: 15835375
[TBL] [Abstract][Full Text] [Related]
13. Randomized controlled clinical trial of corticosteroids plus ACE-inhibitors with long-term follow-up in proteinuric IgA nephropathy.
Manno C; Torres DD; Rossini M; Pesce F; Schena FP
Nephrol Dial Transplant; 2009 Dec; 24(12):3694-701. PubMed ID: 19628647
[TBL] [Abstract][Full Text] [Related]
14. Treatment of mild-to-moderate hypertension with calcium channel blockers: a multicentre comparison of once-daily nifedipine GITS with once-daily amlodipine.
Kes S; Caglar N; Canberk A; Deger N; Demirtas M; Dortlemez H; Kiliccioglu B; Kozan O; Ovunc K; Turkoglu C
Curr Med Res Opin; 2003; 19(3):226-37. PubMed ID: 12803737
[TBL] [Abstract][Full Text] [Related]
15. [Immunosuppressive therapy in IgA glomerulonephritis with chronic renal failure: case study presentation and literature review].
Pozzi C; Del Vecchio L; Locatelli F
G Ital Nefrol; 2002; 19(5):523-8. PubMed ID: 12439840
[TBL] [Abstract][Full Text] [Related]
16. Hong Kong study using valsartan in IgA nephropathy (HKVIN): a double-blind, randomized, placebo-controlled study.
Li PK; Leung CB; Chow KM; Cheng YL; Fung SK; Mak SK; Tang AW; Wong TY; Yung CY; Yung JC; Yu AW; Szeto CC;
Am J Kidney Dis; 2006 May; 47(5):751-60. PubMed ID: 16632013
[TBL] [Abstract][Full Text] [Related]
17. Results of a phase III, 8-week, multicenter, prospective, randomized, double-blind, parallel-group clinical trial to assess the effects of amlodipine camsylate versus amlodipine besylate in Korean adults with mild to moderate hypertension.
Kim SH; Kim YD; Lim DS; Yoon MH; Ahn YK; On YK; Lee JW; Kim IJ; Park JB; Kim JJ; Chung WS; Yang JY; Seo HS; Shin EK; Kim HS;
Clin Ther; 2007 Sep; 29(9):1924-36. PubMed ID: 18035192
[TBL] [Abstract][Full Text] [Related]
18. Study of ACEI versus ARB in managing hypertensive overt diabetic nephropathy: long-term analysis.
Ozturk S; Sar F; Bengi-Bozkurt O; Kazancioglu R
Kidney Blood Press Res; 2009; 32(4):268-75. PubMed ID: 19776644
[TBL] [Abstract][Full Text] [Related]
19. The diabetes subgroup baseline characteristics of the Avoiding Cardiovascular Events Through Combination Therapy in Patients Living With Systolic Hypertension (ACCOMPLISH) trial.
Bakris G; Hester A; Weber M; Dahlof B; Pitt B; Velasquez E; Staikos-Byrne L; Shi V; Jamerson K;
J Cardiometab Syndr; 2008; 3(4):229-33. PubMed ID: 19040592
[TBL] [Abstract][Full Text] [Related]
20. Two multicenter, 8-week, randomized, double-blind, placebo-controlled, parallel-group studies evaluating the efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate essential hypertension.
Philipp T; Smith TR; Glazer R; Wernsing M; Yen J; Jin J; Schneider H; Pospiech R
Clin Ther; 2007 Apr; 29(4):563-80. PubMed ID: 17617280
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]